Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (5.998.300 €): Kleine Gefäßerkrankungen aus mechanistischer Perspektive: Interventionsziele Betroffene Wege und mechanistische Ausbeutung zur Prävention von Schlaganfall und Demenz Hor01.01.2016 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Kleine Gefäßerkrankungen aus mechanistischer Perspektive: Interventionsziele Betroffene Wege und mechanistische Ausbeutung zur Prävention von Schlaganfall und Demenz
Stroke and dementia rank among the most pressing health issues in Europe. Cerebral small vessel diseases (SVDs) have emerged as a central link between these two major co-morbidities. SVDs account for more than 30% of strokes and at least 40% of dementia cases. They encounter multiple distinct diseases that can be separated based on their underlying genetic defects, risk factors, and clinical presentations. Despite this profound impact on human health, there are no treatments with proven efficacy against SVDs. The applicants have made major progress in identifying key mechanisms involved in SVDs and their co-morbidities. We recently identified blood pressure variability as a major independent risk factor for multiple SVDs, stroke, and dementia and illuminated the roles of the blood brain barrier and the extracellular matrix in small vessel function. We further identified novel molecular pathways (TIMP3, LTBP1, TGFß) that are shared between different SVDs and thus point towards common mechanisms. This EU network, which brings together basic scientists and academic clinicians, will make use of novel animal models and expertly phenotyped patient cohorts to identify key mechanisms common to multiple SVDs and determine how these mechanisms contribute to individual SVDs. We will: i) identify common molecular, cellular, and physiological mechanisms that compromise the function of microvessels in different SVDs; ii) determine how these common mechanistic defects intersect to drive brain damage; and iii) validate the relevance of mechanisms through interventions in experimental systems (isolated microvessels and in vivo) and in patients (exploratory proof of concept trials). Our resources including novel animal models and state-of-the art technologies (e.g. proteomics & ultra-high field MRI) as well as expertise in clinical trials support the feasibility of the approach. In fact, studies by the applicants already revealed novel attractive targets for therapeutic intervention.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| ARTTIC INNOVATION GmbH | 70.609 € |
| Arttic | 219.391 € |
| GABO:MI GESELLSCHAFT für ABLAUFORGANISATION:MILLIARIUM mbH & Co. KG | 22.827 € |
| Institut National de la Sante et de la Recherche Medicale | 555.375 € |
| 309.506 € | |
| Kobenhavns Universitet | 555.375 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 975.167 € |
| Stroke Alliance for Europe | 45.025 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 450.000 € |
| The University of Edinburgh | 580.920 € |
| UNIVERSITAET MUENSTER | 550.486 € |
| Universitair Medisch Centrum Utrecht | 570.875 € |
| Universiteit Maastricht | 512.369 € |
| 580.375 € |
Quelle: https://cordis.europa.eu/project/id/666881
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "ARTTIC INNOVATION GmbH - EU-Förderung (5.998.300 €): Kleine Gefäßerkrankungen aus mechanistischer Perspektive: Interventionsziele Betroffene Wege und mechanistische Ausbeutung zur Prävention von Schlaganfall und Demenz"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
